Quantum-Si Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
16 Agosto 2023 - 5:00PM
Business Wire
Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or
the “Company”), The Protein Sequencing CompanyTM, today announced
that the Compensation Committee of Quantum-Si’s Board of Directors
has granted a non-qualified stock option award to purchase an
aggregate of 200,000 shares of its Class A common stock to one new
employee under the Company’s previously adopted Quantum-Si
Incorporated 2023 Inducement Equity Incentive Plan (the “2023
Inducement Plan”). The stock options were granted as inducements
material to the new employee becoming an employee of Quantum-Si in
accordance with Nasdaq Listing Rule 5635(c)(4).
The 2023 Inducement Plan is used exclusively for the grant of
equity awards to individuals who were not previously employees of
Quantum-Si (or following a bona fide period of non-employment), as
an inducement material to such individuals’ entering into
employment with Quantum-Si, pursuant to Rule 5635(c)(4) of the
Nasdaq Listing Rules.
The options have an exercise price of $2.09 per share, which is
equal to the closing price of Quantum-Si’s Class A common stock on
The Nasdaq Global Market on August 15, 2023, the date of grant of
the options. Each option will vest over a four-year period, with
25% of the shares vesting on the last day of the calendar quarter
that is 12 months after the employee’s start date and the remaining
shares vesting monthly over the following 36-months, subject to the
employee’s continued employment with Quantum-Si on such vesting
dates. The options are subject to the terms and conditions of the
2023 Inducement Plan and the terms and conditions of a stock option
agreement covering the grant.
About Quantum-Si Incorporated Quantum-Si, The Protein
Sequencing CompanyTM, is focused on revolutionizing the growing
field of proteomics. The Company's suite of technologies is powered
by a first-of-its-kind semiconductor chip designed to enable
next-generation single-molecule protein sequencing and digitize
proteomic research in order to advance drug discovery and
diagnostics beyond what has been possible with DNA sequencing.
Learn more at www.quantum-si.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230816618119/en/
Investors Juan Avendano ir@quantum-si.com
Media Michael Sullivan media@quantum-si.com
Quantum Si (NASDAQ:QSI)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Quantum Si (NASDAQ:QSI)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024